# DESCRIPTION

## FIELD OF THE DISCLOSURE

- relate to VEGF inhibitors

## BACKGROUND OF THE DISCLOSURE

- introduce NRP-1 and VEGF-A165 interaction
- describe VEGF signalling pathway
- discuss current anti-angiogenic strategies
- motivate need for new compounds
- summarize prior art peptides
- highlight limitations of prior art

## SUMMARY

- define compound of formula (I)
- describe embodiments of compound of formula (I)

### and R5 is H,

- define groups R1 and R4
- define groups R2 and R5
- define group A

## DETAILED DESCRIPTION OF THE DISCLOSURE

- introduce novel VEGF-A165/NRP-1 inhibitors

### Compounds of the Disclosure

- define compound of formula (I)
- specify groups R1 and R4
- specify groups R2 and R5
- define group A
- specify group A1
- specify group A2
- exclude peptide CKPPR
- clarify non-substituted chemical groups
- define residue for R1 and R4
- define residue for R2 and R5
- define residue for A1 and R3
- define subfamilies of compounds
- define compounds of formula (I-A1)
- define compounds of formula (I-A2)
- define abbreviations for residues
- introduce isomeric form of compound (I)
- define compound of formula (I′)
- specify groups for compound of formula (I′)
- define protecting groups
- specify examples of protecting groups
- define compounds of formula (I)
- describe binding properties to NRP-1
- describe VEGF-A165
- describe NRP-1
- describe sulfhydryl group in compounds of formula (I)
- describe cysteine residue in compounds of formula (I)
- describe binding level of compounds of formula (I) to NRP-1
- describe importance of cysteine residue and arginine residue
- describe proline analogues
- define proline and proline analogues
- describe embodiments of compounds of formula (I) with group A as A1
- describe embodiments of compounds of formula (I) with group A as A2
- describe embodiments of compounds of formula (I) with R2 and R5
- describe embodiments of compounds of formula (I) with R1 and R4
- describe compounds of formula (I-A), (I-B), (I-C), and (I-D)
- describe acid-addition salts of compounds of formula (I)
- describe pharmaceutically acceptable acids
- describe trifluoroacetate salt
- describe pharmaceutically acceptable salts
- describe hydrates and solvates of compounds of formula (I)
- describe mixtures of solvates
- describe racemic, enantiomeric, diastereoisomeric, or tautomeric forms
- describe pharmaceutically acceptable salts of compounds of formula (I)
- describe embodiments of compounds of formula (I)

### Methods for Preparing Compounds of Formula (I)

- define first preparation method
- specify group A as group (A1)
- describe R1 and R4 options
- describe R2 and R5 options
- specify A as formula A1′
- outline steps for preparing compound of formula (I)
- describe step a) alpha amine group deprotection
- describe step b) alpha amine group deprotection
- describe step c) alpha amine group deprotection
- describe step d) alpha amine group deprotection
- describe step e) epsilon amine group deprotection
- describe step f) removing compound from solid support
- define second preparation method
- specify group A as group (A2)
- describe R1 and R4 options
- describe R2 and R5 options
- specify A as formula A2
- outline steps for preparing compound of formula (I)
- describe steps a) to e) for second preparation method
- describe step f) removing compound from solid support

### Pharmaceutical Compositions

- introduce pharmaceutical composition
- specify compound of formula (I) as active ingredient
- describe optional combination with pharmaceutically compatible excipients
- specify compounds of formula (I) for prophylactic or therapeutic use
- describe composition formulation and administration
- outline dosage and treatment considerations

### Therapeutic Uses

- introduce compound for medicinal use
- specify pharmaceutically acceptable salts and forms
- relate to preventing or treating VEGF-A165/NRP-1 interaction
- relate to preparing medicament for preventing or treating VEGF-A165/NRP-1 interaction
- specify use for preventing or treating angiogenesis mediated by VEGF-A165/NRP-1 interaction
- relate to preparing medicament for preventing or treating angiogenesis mediated by VEGF-A165/NRP-1 interaction
- specify use for treating several disorders
- define subject as human or non-human animal
- define cancer
- specify examples of cancers
- relate to preventing or treating cancer
- relate to preparing medicament for preventing or treating cancer
- specify use for preventing or treating cancer
- relate to preparing medicament for preventing or treating cancer
- define methods
- specify prophylactic or therapeutic method for inhibiting VEGF-A165/NRP-1 interaction
- specify method for preventing or treating disease involving VEGF-A165/NRP-1 interaction
- specify method for preventing or treating angiogenesis mediated by VEGF-A165/NRP-1 interaction
- specify method for preventing or treating cancer
- specify types of cancers that may be prevented or treated
- specify medical method as prophylactic or therapeutic
- specify administration routes
- specify pharmaceutical composition administration
- specify topical administration
- specify aerosol delivery
- specify other administration routes
- specify galenic formulation adaptation

## EXAMPLES

### Example

- introduce synthesis of peptide VEGF-A165/NRP-1 inhibitors
- describe solid phase peptide synthesis (SPPS) procedure
- specify protecting groups for functional groups
- describe Wang resin for peptide synthesis
- specify coupling reagents for peptide bonds
- describe cleavage of peptide from resin
- specify purification method using HPLC
- convert to pharmaceutically acceptable salt
- introduce solid phase synthesis of peptides of formula (I)
- describe synthesis of compound of formula (I) H-Cys-Lys(hArg)-Dab-ΔPro-Arg-OH
- specify Fmoc-L-Arg(Pbf) Wang resin
- describe Fmoc-deprotection step
- specify Kaiser test for monitoring Fmoc cleavage
- describe coupling of Fmoc-ΔPro-OH
- specify acetaldehyde/chloranil test for monitoring coupling reaction
- describe coupling of Fmoc-Dab(Boc)-OH
- describe Fmoc-deprotection and washing steps
- describe coupling of Fmoc-Lys(Alloc)-OH
- describe Alloc-deprotection step
- describe coupling of Fmoc-hArg(Pbf)-OH
- describe Fmoc-deprotection and washing steps
- introduce example 3: solid phase synthesis of compound of formula (I) H-Lys(Cys-hArg)-Dab-ΔPro-Arg
- describe synthesis of compound of formula (I) H-Lys(Cys-hArg)-Dab-ΔPro-Arg-OH
- specify Fmoc-L-Arg(Pbf) Wang resin
- describe Fmoc-deprotection and washing steps
- describe coupling of Fmoc-ΔPro-OH
- describe coupling of Fmoc-Dab(Boc)-OH
- describe coupling of Boc-Lys(Fmoc)-OH
- describe coupling of Fmoc-hArg(Pbf)-OH
- describe Fmoc-deprotection and washing steps
- describe final steps of synthesis
- describe purification and analysis of final product

